Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Wide metastatic spreading in infiltrating lobular carcinoma of the breast.
Ferlicot S, Vincent-Salomon A, Médioni J, Genin P, Rosty C, Sigal-Zafrani B, Fréneaux P, Jouve M, Thiery JP, Sastre-Garau X. Ferlicot S, et al. Among authors: medioni j. Eur J Cancer. 2004 Feb;40(3):336-41. doi: 10.1016/j.ejca.2003.08.007. Eur J Cancer. 2004. PMID: 14746850
Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Daban A, Gonnin C, Phan L, Saldmann A, Granier C, Lillo-Lelouet A, Le Beller C, Pouchot J, Weiss L, Tartour E, Fabre E, Medioni J, Oudard S, Vano YA, Dragon-Durey MA, Simonaggio A. Daban A, et al. Among authors: medioni j. Oncoimmunology. 2023 May 11;12(1):2204754. doi: 10.1080/2162402X.2023.2204754. eCollection 2023. Oncoimmunology. 2023. PMID: 37187974 Free PMC article.
Acute autoimmune sensorineural hearing loss associated with Crohn's disease.
Bachmeyer C, Leclerc-Landgraf N, Laurette F, Coutarel P, Cadranel JF, Médioni J, Dhôte R, Mougeot-Martin M. Bachmeyer C, et al. Among authors: medioni j. Am J Gastroenterol. 1998 Dec;93(12):2565-7. doi: 10.1111/j.1572-0241.1998.00720.x. Am J Gastroenterol. 1998. PMID: 9860428
Medullary breast carcinoma: prognostic implications of p53 expression.
Dendale R, Vincent-Salomon A, Mouret-Fourme E, Savignoni A, Medioni J, Campana F, Vilcoq JR, de la Rochefordière A, Soussi T, Asselain B, de Cremoux P, Fourquet A. Dendale R, et al. Among authors: medioni j. Int J Biol Markers. 2003 Apr-Jun;18(2):99-105. doi: 10.5301/jbm.2008.1279. Int J Biol Markers. 2003. PMID: 12841678 Free article.
Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study.
Oudard S, Thiam R, Fournier LS, Medioni J, Lamuraglia M, Scotte F, Fabre E, Kim D, Kpamegan E, Panneerselvam A, Cuenod CA. Oudard S, et al. Among authors: medioni j. Eur J Cancer. 2012 Jul;48(10):1512-8. doi: 10.1016/j.ejca.2012.01.027. Epub 2012 Feb 16. Eur J Cancer. 2012. PMID: 22342553 Clinical Trial.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. Pivot X, et al. Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11. Lancet Oncol. 2013. PMID: 23764181 Clinical Trial.
133 results